Xarelto Paediatric VTE PASS Drug Utilization Study: An observational, longitudinal, multisource drug utilization safety study to evaluate the drug use patterns and safety of rivaroxaban oral suspension in children under two years with venous thromboembolism (XAPAEDUS)

**First published:** 10/05/2023 **Last updated:** 04/07/2025





# Administrative details

**EU PAS number** 

**EUPAS46800** 

Study ID

104927

**DARWIN EU® study** 

No

Study countries	
Denmark	
France	
Spain	
Sweden	

#### Study description

This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE). VTE is a condition in which blood clots form in the veins, usually in the leg. This can cause pain and swelling. The clot can also break apart and travel in the blood to the lungs where it can block the blood flow. This can be life threatening.

Rivaroxaban is approved for doctors to prescribe to children with VTE, but there is limited information about how it is used, how well it works, and how safe it is in children under 2 years old. Children in this study are already receiving or will receive rivaroxaban or other currently used medicines for VTE from their doctor according to the approved product information. The purpose of this study is to collect information on the pattern of use and safety of rivaroxaban and other standard medicines for VTE in children under 2 years old.

The main information that researchers will collect in this study: Age, gender, and other information about the child and their illness. Type of VTE treatment given to the child.

Occurrence of medically important bleeding and its severity. Further information that researchers will collect: Changes in the characteristics of the children given VTE treatment (e.g. changes in the age range of children given VTE treatment) and changes in the treatment pattern for VTE. Return of VTE symptoms. Types of doctors who prescribe VTE treatment and their set-up (e.g. special clinics versus hospitals). Besides this data collection, no further tests or examinations are needed in this study.

The data for this study will be collected from electronic health records and health insurance claims data until 2026. Researchers will observe each child during treatment until the child has a bleeding episode, VTE symptoms return, VTE treatment ends, or death, their information is no longer available, or the study ends.

## **Study status**

Planned

# Research institutions and networks

# Institutions

# Bayer AG

First published: 01/02/2024

**Last updated:** 01/02/2024

Institution

Aarhus University & Aarhus University Hospital	
DEPARTMENT OF CLINICAL EPIDEMIOLOGY	
Denmark	
First published: 20/07/2021	
Last updated: 02/04/2024	
Institution	

## Contact details

## **Study institution contact**

Bayer Clinical Trials Contact BAYER AG clinical-trials-contact@bayer.com

Study contact

clinical-trials-contact@bayer.com

## **Primary lead investigator**

Bayer Clinical Trials Contact BAYER AG

**Primary lead investigator** 

# Study timelines

## Date when funding contract was signed

Planned: 31/12/2022

## Study start date

Planned: 31/12/2025

## Date of final study report

Planned: 28/02/2030

# Sources of funding

Pharmaceutical company and other private sector

# More details on funding

# Study protocol

22195 Study Protocol Redacted V2.1 2022-11-16.pdf (735.21 KB)

# Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

# Methodological aspects

# Study type

# Study type list

# **Study topic:**

Disease /health condition

Human medicinal product

## **Study type:**

Non-interventional study

#### Scope of the study:

#### Drug utilisation

## Main study objective:

- Clinical characteristics and demographics of patients when using anticoagulation therapy for the treatment of VTE (rivaroxaban oral suspension or SOC)
- Use of anticoagulation therapy (including selected drug, dose, and duration) for treatment of VTE
- Incidence and severity of bleeding (major bleeding, and clinically relevant nonmajor bleeding) according to anticoagulation therapy

# Study Design

## Non-interventional study design

Cohort

# Study drug and medical condition

# Study drug International non-proprietary name (INN) or common name RIVAROXABAN

## **Anatomical Therapeutic Chemical (ATC) code**

(B01AF01) rivaroxaban

rivaroxaban

#### Medical condition to be studied

Embolism venous

# Population studied

## **Age groups**

Preterm newborn infants (0 - 27 days)

Term newborn infants (0 - 27 days)

Infants and toddlers (28 days - 23 months)

#### **Estimated number of subjects**

850

# Study design details

#### **Outcomes**

- Demographic characteristics of patients Characteristics of index VTE Comorbidities reported in the previous six months before index date, or since date of birth for children less than six months
- Major bleeding according to anticoagulation therapy
- Clinically Relevant Non-Major (CRNM) bleeding according to anticoagulation therapy Please see more in protocol, Time trends by calendar year in patient characteristics
- Time trends by calendar year in anticoagulation treatment patterns
- Incidence of recurrent symptomatic VTE according to anticoagulation therapy
- Physician specialty and care settings (inpatient care, secondary outpatient care, primary care) for prescriptions of anticoagulation therapy

#### Data analysis plan

Given the study objectives the analyses will be descriptive, with no intent for hypothesis generating or testing between exposure categories. Incidences in Rivaroxaban and SOC cohorts will be compared only in an exploratory sense and no confirmatory statistical tests will be performed. All analyses will be conducted separately by country and data source. Besides, combined analyses

of aggregated data across data sources will be provided, as applicable.

Categorical variables will be presented as counts (n), and proportions (%), with

95% CI where relevant. Continuous variables will be presented as means with

standard deviation and as medians with interquartile range, where appropriate.

# **Documents**

#### **Study report**

22195 Progress report1 Redacted V1.0 2023-10-31.pdf (191.38 KB)

# Data management

# **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

# Data sources

#### Data source(s)

Sweden National Prescribed Drugs Register / Läkemedelsregistret
The Information System for Research in Primary Care (SIDIAP)

#### Data source(s), other

Système National Des Données De Santé (SNDS) France, Danish Register of Medicinal Products Statistics (RMPS) Denmark, Danish Hospital Patient Medication Register (SMR) Denmark, Swedish National Patient Register (NPR) Sweden, Swedish Cause of Death Register Sweden

## **Data sources (types)**

Administrative healthcare records (e.g., claims)

Electronic healthcare records (EHR)

# Use of a Common Data Model (CDM)

## **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

## **Check completeness**

Unknown

## **Check stability**

Unknown

## **Check logical consistency**

Unknown

# Data characterisation

#### **Data characterisation conducted**